# Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome

> **NCT02906371** · PHASE1 · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 80 (actual)

## Conditions studied

- Lymphoblastic Leukemia, Acute, Childhood

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** Tocilizumab
- **BIOLOGICAL:** CART 19

## Key facts

- **NCT ID:** NCT02906371
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2020-03-11
- **Final completion:** 2021-06-30
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2021-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02906371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02906371, "Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02906371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*